Fourth quarter results and preliminary financials for 2025 for Medistim ASA

27 Feb 2026 08:30 CET

Record sales for both the quarter and year. 20.6% growth in the fourth quarter,
ending at NOK 182.3 (MNOK 151.1). 24.4% growth for the year, ending at MNOK
699.8 (MNOK 562.6).

Currency neutral sales of own products were up 25.6 % for the quarter and 28.3 %
for the year
Strong currency neutral growth for the quarter in AMERICAS and EMEA, up 44.3%
and 24.4% respectively. APAC down 24.2 %, however, up 40.0 % for the year.

Third-party distributor sales in Scandinavia increased 2.2% for the quarter and
12.7% for the Year

Strong operating profit (EBIT) growing by 64.0% to MNOK 42.3 for the quarter,
resulting in
23.2% EBIT margin (MNOK 25.8, 17.1% margin). Record EBIT for the year, growing
50.0% to MNOK 196.2, resulting in 28.0% EBIT margin (MNOK 131.1, 23.3% margin).

Recurring sales remained high at 70.1% (73.7%). Strong capital sales reduce
recurring sales in % compared to last year.

Solid cash position at quarter end with MNOK 212.1. The company has no
interest-bearing bank loans.

The Board of Directors will suggest to the General Assembly a dividend of NOK
8.00 per share, total dividend payment of MNOK 146.2.

More information:
Access the news on Oslo Bors NewsWeb site

667094_Q4 2025 - Financial Presentation-FINAL.pdf
667094_Q4 2025 Financial Report-Final 26.02.2026.pdf